Aristotle Capital Management 13F: Cuts Alcon (ALC) Stake by $32M

Aristotle Capital Management has reduced its stake in Alcon Inc. (NYSE: ALC), according to its latest Form 13F filing with the SEC. The firm sold 481,233 shares, trimming its position by 4.35%. As of the end of the reporting period, Aristotle held 10,584,374 shares valued at approximately $707.6 million.

What Changed in Aristotle Capital Management's Alcon Position

Aristotle Capital Management's decision to reduce its stake in Alcon saw its holdings decrease from 11,065,607 shares to 10,584,374 shares. This reduction of 481,233 shares represents a 4.35% decrease in its position, reflecting a strategic adjustment in its investment portfolio.

Other Institutional Activity in Alcon

Several other major institutional investors made notable changes to their Alcon holdings. Bank of New York Mellon Corp increased its stake by 2,478,144 shares, bringing its total to 15,669,662 shares worth about $1.18 billion. Vanguard Capital Management LLC acquired 14,871,607 shares, marking a significant addition to its holdings, now valued at approximately $1.12 billion. FMR LLC also boosted its position by 1,668,163 shares to a total of 12,426,992 shares, valued at around $938.3 million. Meanwhile, AKO Capital LLP added 1,637,956 shares, raising its total to 9,324,656 shares worth $695.6 million.

Alcon Inc. Stock Up 3.2%

Shares of Alcon Inc. (NYSE: ALC) were trading at $66.85. The company has a market capitalization of about $32.6 billion and a P/E ratio of 40.03, indicating investor expectations of future earnings growth. Alcon's stock has experienced a 52-week low of $61.84 and a high of $92.55. The stock's 50-day moving average is $70.72, while the 200-day moving average stands at $76.34. Alcon maintains a strong liquidity position with a current ratio of 2.20 and a quick ratio of 1.22.

Recent Earnings

Alcon reported revenue of $10.63 billion, reflecting a growth rate of 9.4%. The company's earnings per share (EPS) stood at $1.67, with a net margin of 7.7%. Return on equity (ROE) was reported at 3.71%. Alcon is scheduled to announce its next earnings results on May 5, 2026.

Dividend

Alcon offers an annual dividend rate of $0.36, yielding 0.54% based on current share prices. The company's dividend payout ratio is 20.39%, indicating a conservative approach to returning profits to shareholders.

Insider Buying and Selling at Alcon Inc.

Recent insider activity at Alcon includes several sales. On February 26, 2026, Sergio Duplan sold 15,000 shares at an average price of $86.54. Laurent Attias also sold 2,412 shares at $86.91 on the same day. These transactions were not executed under a pre-arranged trading plan.

Analysts Set New Price Targets

On May 8, 2026, Barclays maintained its hold rating on Alcon with a price target of $78. Wells Fargo, Mizuho, and Baird maintained buy ratings with price targets of $86, $85, and $90, respectively, on May 7, 2026. The consensus among 15 analysts is a buy rating, with a mean target price of $87.92.

About Alcon Inc.

Alcon Inc., headquartered in Geneva, Switzerland, is a leading global player in the eye care industry. The company operates in two segments: Surgical and Vision Care. It develops and sells surgical equipment, intraocular lenses, and vision care products like contact lenses and eye care solutions. With a workforce of around 25,000 employees, Alcon is led by CEO David J. Endicott.

Bottom Line

Aristotle Capital Management's recent filing shows a strategic reduction in its position in Alcon Inc., reflecting adjustments in its investment approach. Investors closely monitor these filings to gauge fund sentiment, although it's important to remember that 13F filings are historical and may not reflect current positions. Alcon remains a significant player in the healthcare sector, drawing attention from both institutional investors and analysts.